切换至 "中华医学电子期刊资源库"

中华脑血管病杂志(电子版) ›› 2024, Vol. 18 ›› Issue (03) : 265 -269. doi: 10.11817/j.issn.1673-9248.2024.03.011

临床研究

hs-CRP、Lp-PLA2和S100β与缺血性脑小血管病患者认知障碍的相关性
欧春影1, 李晓宾1, 郭靖1, 许可1, 王梦1, 安晓雷1,()   
  1. 1. 221000 江苏徐州,徐州市中心医院神经内科,南京医科大学徐州临床医学院
  • 收稿日期:2023-11-21 出版日期:2024-06-01
  • 通信作者: 安晓雷
  • 基金资助:
    江苏省科技项目(BL2014028); 江苏省卫生健康委科研课题(Ym2023012); 徐州市科技项目(KC22175)

Correlation of hs-CRP, Lp-PLA2, and S100β with vascular cognitive impairment in patients with ischemic small vascular disease

Chunying Ou1, Xiaobin Li1, Jing Guo1, Ke Xu1, Meng Wang1, Xiaolei An1,()   

  1. 1. Department of Neurology, Xuzhou Central Hospital; The Xuzhou School of Clinical Medicine of Nanjing Medical University,描述,组间比较采用独立样本 Xuzhou 221000, China
  • Received:2023-11-21 Published:2024-06-01
  • Corresponding author: Xiaolei An
引用本文:

欧春影, 李晓宾, 郭靖, 许可, 王梦, 安晓雷. hs-CRP、Lp-PLA2和S100β与缺血性脑小血管病患者认知障碍的相关性[J]. 中华脑血管病杂志(电子版), 2024, 18(03): 265-269.

Chunying Ou, Xiaobin Li, Jing Guo, Ke Xu, Meng Wang, Xiaolei An. Correlation of hs-CRP, Lp-PLA2, and S100β with vascular cognitive impairment in patients with ischemic small vascular disease[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(03): 265-269.

目的

研究缺血性脑小血管病(CSVD)患者高敏C反应蛋白(hs-CRP)、脂蛋白相关磷脂酶A2(Lp-PLA2)和钙结合蛋白S100β与认知障碍的相关性。

方法

收集2020年6月至2022年6月徐州市中心医院神经内科门诊及住院的缺血性CSVD患者80例作为观察组,采用蒙特利尔认知评估(MoCA)量表对受试者认知功能进行评分,并根据评分将缺血性CSVD患者分为非认知障碍组和认知障碍组。选择同期40例健康体检者作为健康对照组。测定缺血性CSVD患者及健康体检者血清中hs-CRP、Lp-PLA2和S100β的水平。采用单因素方差分析3组hs-CRP、Lp-PLA2和S100β的差异并采用Scheffe法进行组间两两比较,然后进行Logistic多因素回归分析,采用Spearman相关分析各独立影响因素与MoCA评分的相关性。

结果

认知障碍组患者(48例)血清中hs-CRP[(7.6±4.01)ng/ml]、Lp-PLA2[(55.77±35.59)pg/ml]、S100β[(0.66±0.047)μg/L]均高于非认知障碍组[32例,(4.35±3.99)ng/ml、(37.71±8.45)pg/ml、(0.62±0.058)μg/L]和对照组[(1.13±0.84)ng/ml、(24.10±3.16)pg/ml、(0.56±0.039)μg/L],差异均具有统计学意义(P均<0.05)。Logistic回归分析显示,血清hs-CRP、Lp-PLA2、S100β是缺血性CSVD患者认知障碍的独立危险因素(OR=2.619,P<0.001;OR=1.814,P<0.001;OR=2.340,P<0.001);hs-CRP、Lp-PLA2、S100β与MoCA评分均呈负相关(r=-0.533,P<0.001;r=-0.263,P=0.018;r=-0.369,P=0.009)。

结论

hs-CRP、Lp-PLA2、S100β与CSVD患者认知功能呈负相关,是其独立危险因素。

Objective

To investigate the correlation between high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), and calcium-binding protein β (S100β) and cognitive impairment in patients with ischemic small cerebral vascular disease (CSVD).

Methods

A total of 80 patients with ischemic CSVD were collected as observation group and were divided into non-cognitive impairment and cognitive impairment groups according to the score of Montreal cognitive assessment (MoCA). An additional 40 healthy people were selected as the healthy control group. Serum levels of hs-CRP, Lp-PLA2, and S100β in patients with ischemic CSVD and healthy people were measured. The levels of hs-CRP, Lp-PLA2, and S100β were analyzed using one-way Anova, followed by Logistic multiple regression analysis and Spearman correlation analysis to determine their correlation.

Results

There were no significant differences in general conditions among the three groups. The serum levels of hs-CRP, Lp-PLA2, and S100β in patients with cognitive impairment [(7.6±4.01) ng/ml, (55.77±35.59) pg/ml, (0.66±0.047) μg/L] were higher than those in patients without cognitive impairment [(4.35±3.99) ng/ml, (37.71±8.45) pg/ml, (0.62±0.058) μg/L] and in healthy controls [(1.13±0.84) ng/ml, (24.10±3.16) pg/ml, (0.56±0.039) μg/L]. Logistic regression analysis showed that serum hs-CRP, Lp-PLA2, and S100β were independent risk factors for cognitive impairment in patients with CSVD (OR=2.619, P<0.001; OR=1.814, P<0.001; OR=2.340, P<0.001). hs-CRP, Lp-PLA2, and S100β were negatively correlated with MoCA scores (r=-0.533, r=-0.263, r=-0.369; all P<0.05).

Conclusion

hs-CRP, Lp-PLA2, S100β were negatively correlated with the cognitive function in CSVD and were identified independent risk factors.

表1 3组研究对象的一般临床资料比较
表2 3组研究对象血清hs-CRP、Lp-PLA2、S100β和MoCA评分比较(
x¯±s
表3 缺血性脑小血管病患者认知障碍的Logistic回归分析
1
祁林瑞, 曾嵘, 胡风云. 炎性及代谢指标与脑小血管病认知障碍的相关性 [J/OL]. 中华脑血管病杂志(电子版), 2022, 16(1): 32-37.
2
刘洋, 王蕊, 张祥, 等. 症状性小动脉硬化脑小血管病患者脑微出血的危险因素分析 [J]. 中国卒中杂志, 2023, 18(4): 440-449.
3
Chojdak-Lukasiewicz J, Dziadkowiak E, Zimny A, et al. Cerebral small vessel disease: a review [J]. Adv Clin Exp Med, 2021, 30(3): 349-356.
4
Teng Z, Dong Y, Zhang D, et al. Cerebral small vessel disease and post-stroke cognitive impairment [J]. Int J Neurosci, 2017, 127(9): 824-830.
5
欧春影, 李传玲, 安晓雷, 等. 脑卒中后血管性认知功能障碍的危险因素分析及发病风险预测 [J]. 山东医药, 2019, 59(20): 68-71.
6
高晗清, 薛群, 段晓宇, 等. hs-CRP、Lp-PLA2联合CT血管造影在TIA及轻型脑卒中急性期疾病进展中的预测价值 [J]. 山东医药, 2017, 57(41): 85-87.
7
郭晖, 徐文君, 宋仁兴, 等. 支架取栓术后亚低温对急性大血管闭塞性缺血性脑卒中患者血清S100β蛋白水平的影响 [J/OL]. 中华脑血管病杂志(电子版), 2020, 14(05): 275-280.
8
彭斌. 在血管再通时代关注脑小血管病 [J]. 中国脑血管病杂志, 2019, 16(10): 505-507.
9
钟曦, 王伊龙. 血清生物标志物与脑小血管病关系研究进展 [J]. 中国卒中杂志, 2019, 14(11): 1140-1145.
10
Gilani STA, Khan DA, Rauf A, et al. Early diagnosis of coronary artery disease by inflammatory biomarkers of atherosclerosis in patients with angina [J]. J Interferon Cytokine Res, 2022, 42(9): 493-500.
11
田雨, 潘岳松, 管玲, 等. 高敏C反应蛋白与老年脑小血管病疾病总负荷的相关性 [J].中华老年心脑血管病杂志, 2021, 23(7): 720-723.
12
De Stefano A, Mannucci L, Tamburi F, et al. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases [J]. Int J lmmunopathol Pharmacol, 2019, 33: 1-4.
13
Santoso A, Heriansyah T, Rochman MS. Phosph01ipase A2 is an inflammatory predictor in cardiovascular diseases: is there any spacious room to prove the causation? [J]. Curr Cardiol Rev, 2020, 16(1): 3-10.
14
Zhu S, Wei X, Yang X, et al. P1asma lipoprotein—associated phospholipase A2 and superoxide dismutase are independent predicators of cognitive impairment in cerebral small vessel disease patients: diagnosis and assessment [J]. Aging Dis, 2019, 10(4): 834-846.
15
Sarkulova Z, Tokshilykova A, Sarkulov M, et al. [The level of s100β in blood serum as a prognostic factor of outcome in secondary brain lesions] [J]. Georgian Med News, 2021(321): 162-168.
16
Chen L, Chen L, Lv Y, et al. Tetrandrine ameliorates cognitive impairment via inhibiting astrocyte-derived S100B activation in a rat model of chronic cerebral hypoperfusion [J]. Neurol Res, 2013, 35(6): 614-621.
[1] 张轩, 冯明, 王倩, 薛蓉. 舒脑欣滴丸对脑小血管病患者客观睡眠和炎症标志物的影响[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(03): 140-145.
[2] 李瑞雨, 王新亮, 徐丛丛, 刘严泽, 张雪竹. 国内外血管性认知障碍临床试验注册现状分析[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(01): 14-20.
[3] 张萌, 喻中华. 阿尔茨海默病患者血清脂联素、Lp-PLA2、IL-17的表达及与认知功能的相关性分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(06): 358-363.
[4] 常文轩, 王婷, 刘伟, 蓝天琦, 彭静, 汪诗瑶, 张晓鹏, 冯晨, 宫雪梅, 朱敏. 脑小血管病所致执行障碍的研究进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(03): 179-182.
[5] 高倩, 李晓芳, 杨亚昭, 张静, 崔蕾, 杨立青, 夏艳敏. 甲状腺激素及Apelin在CSVD致认知障碍的研究进展[J]. 中华临床医师杂志(电子版), 2024, 18(02): 201-206.
[6] 沈洁, 谢鸿阳, 夏翠俏, 黄勇华. 脑小血管病与认知衰弱的研究现状[J]. 中华脑血管病杂志(电子版), 2024, 18(02): 181-184.
[7] 李洪远, 董书宇, 鹿寒冰. 血清Hcy、sdLDL-C、Lp-PLA2水平对短暂性脑缺血发作进展为急性脑梗死的预测效能[J]. 中华脑血管病杂志(电子版), 2024, 18(01): 40-48.
[8] 赵晓晓, 邱嘉婷, 张懿姝, 张蓉, 张棚, 刘晓蕾. 丁苯酞在各类型认知障碍治疗中的应用研究进展[J]. 中华脑血管病杂志(电子版), 2024, 18(01): 19-26.
[9] 丁文华, 王育伟, 邱景景, 杨琼, 耿玉荣. 脑小血管病影像学标志物与运动障碍研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 429-434.
[10] 白明悦, 杨淑娜, 胡红梅, 胡文立. 透析患者脑小血管病患病情况的研究现状及其机制探讨[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 505-509.
[11] 晏美娟, 邵礼晖. 高水平脂蛋白(a)与无“三高”老年人群小动脉硬化型脑小血管病的相关性研究[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 458-463.
[12] 刘琳, 张奇山, 廖蔓倩, 陈余榕, 李倍, 何玉成, 唐圣桃. HTRA1相关常染色体显性脑小血管病家系报告并文献复习[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 379-385.
[13] 王道合, 施媛媛. 8-iso-PGF2α及P选择素在评估脑小血管病患者认知功能中的价值[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 364-368.
[14] 胡红梅, 胡文立. 脑小血管病总负担评估量表的研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 145-149.
[15] 李卓然, 胡文立. 内皮功能、炎症、神经系统退行性疾病的生物标志物与小动脉硬化型CSVD的关联[J]. 中华脑血管病杂志(电子版), 2023, 17(01): 57-60.
阅读次数
全文


摘要